Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1986 Oct;89(2):313–319. doi: 10.1111/j.1476-5381.1986.tb10262.x

The haemodynamic and metabolic effects of tolmesoxide with special reference to impaired myocardial function.

J E Mackenzie, R J Marshall, J R Parratt
PMCID: PMC1917022  PMID: 3779213

Abstract

The haemodynamic, metabolic and regional blood flow effects of the vasodilator, tolmesoxide (1 mg kg-1 min-1 for 20 min by intravenous infusion) were examined in two groups of greyhound dogs anaesthetized with alpha-chloralose and mechanically ventilated. One group of dogs was thoracotomized and subjected to acute coronary artery occlusion. In these dogs tolmesoxide was infused 2.5 h after occlusion when there was evidence of impaired myocardial function. Tolmesoxide administration resulted in marked systemic hypotension which was associated with myocardial stimulation (increase in heart rate and LVdP/dtmax). These effects were less marked in thoracotomized dogs subjected to coronary artery occlusion. Cardiac stimulation was attenuated by pretreatment with the beta-adrenoceptor antagonist, atenolol. Peripheral resistance and left ventricular end-diastolic pressure (LVEDP) were reduced by tolmesoxide. In spite of the systemic hypotension, the marked reduction in LVEDP resulted in an enhanced subendocardial driving pressure and an increased blood flow to ischaemic regions of the left ventricular wall as measured with Xe133 clearance. Blood flow to normal regions of the left ventricular wall was also increased by tolmesoxide. A metabolic and respiratory acidosis may have contributed to the haemodynamic effects of tolmesoxide. Plasma renin levels were significantly elevated by the drug. Tolmesoxide administration thus resulted in cardiac stimulation, reduced both pre-load and after-load, yet maintained coronary and pulmonary perfusion. This haemodynamic profile of tolmesoxide would explain the beneficial effects obtained with this drug in the treatment of cardiac failure.

Full text

PDF
313

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collier J. G., Lorge R. E., Robinson B. F. Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 1978 Jan;5(1):35–44. doi: 10.1111/j.1365-2125.1978.tb01595.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Doxey J. C. Tolmesoxide, a drug that lowers blood pressure by a direct relaxant effect on vascular smooth muscle. Br J Pharmacol. 1978 May;63(1):111–118. doi: 10.1111/j.1476-5381.1978.tb07780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Epstein S. E., Stampfer M., Beiser G. D. Role of the capacitance and resistance vessels in vasovagal syncope. Circulation. 1968 Apr;37(4):524–533. doi: 10.1161/01.cir.37.4.524. [DOI] [PubMed] [Google Scholar]
  4. Hyde R. W. Clinical interpretation of arterial oxygen measurements. Med Clin North Am. 1970 May;54(3):617–629. [PubMed] [Google Scholar]
  5. Lauwers P., Nievel J. G. Haemodynamic changes in heart failure induced by a new vasodilator tolmesoxide. Eur J Clin Pharmacol. 1982;21(6):473–477. doi: 10.1007/BF00542041. [DOI] [PubMed] [Google Scholar]
  6. Lloyd-Jones J. G., Henson R., Nichols J. D., Greenslade D., Clifford J. M. Pharmacokinetics of intravenous and oral tolmesoxide. Eur J Clin Pharmacol. 1981 Jan;19(2):119–125. doi: 10.1007/BF00568398. [DOI] [PubMed] [Google Scholar]
  7. Marshall R. J., Parratt J. R. Drug-induced changes in blood flow in the acutley ischaemic canine myocardium;relationship to subendocardial driving pressure. Clin Exp Pharmacol Physiol. 1974 Mar-Apr;1(2):99–112. doi: 10.1111/j.1440-1681.1974.tb00531.x. [DOI] [PubMed] [Google Scholar]
  8. Marshall R. J., Parratt J. R., Ledingham I. M. Changes in blood flow and oxygen consumption in normal and ischaemic regions of the myocardium following acute coronary artery ligation. Cardiovasc Res. 1974 Mar;8(2):204–215. doi: 10.1093/cvr/8.2.204. [DOI] [PubMed] [Google Scholar]
  9. Marshall R. J., Parratt J. R. Prophylactic lignocaine and early post-coronary artery occlusion dysrhythmias in anaesthetized greyhounds. Br J Pharmacol. 1980;71(2):597–600. doi: 10.1111/j.1476-5381.1980.tb10978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mikkelsen E., Pedersen O. L. Comparative studies on the effects of tolmesoxide (Rx71107), a tolmesoxide metabolite (Rx71112) and nifedipine in isolated blood vessels. Br J Pharmacol. 1981 Aug;73(4):799–805. doi: 10.1111/j.1476-5381.1981.tb08731.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Miller R. R., Palomo A. R., Brandon T. A., Hartley C. J., Quinones M. A. Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts. Am Heart J. 1981 Sep;102(3 Pt 2):500–508. doi: 10.1016/0002-8703(81)90738-9. [DOI] [PubMed] [Google Scholar]
  12. O'Boyle C. P., Laher M., O'Brien E. T., O'Malley K., Kelly J. G. The clinical pharmacology of tolmesoxide. A new vasodilator antihypertensive agent. Eur J Clin Pharmacol. 1982;23(2):93–97. doi: 10.1007/BF00545961. [DOI] [PubMed] [Google Scholar]
  13. O'Boyle C. P., McGarry K., Fitzgerald D., Kelly J. G., Horgan J., O'Malley K. Clinical pharmacology of tolmesoxide in refractory heart failure. Eur J Clin Pharmacol. 1981;21(3):169–172. doi: 10.1007/BF00627915. [DOI] [PubMed] [Google Scholar]
  14. Parratt J. R., Marshall R. J., Ledingham I. M. Interventions for improving blood flow, oxygen availability and the balance between oxygen supply and demand in the acutely ischaemic myocardium. J Physiol (Paris) 1980;76(7):791–803. [PubMed] [Google Scholar]
  15. Radvany P., Davis M. A., Muller J. E., Maroko P. R. Effects of minoxidil on coronary collateral flow and acute myocardial injury following experimental coronary artery occlusion. Cardiovasc Res. 1978 Feb;12(2):120–126. doi: 10.1093/cvr/12.2.120. [DOI] [PubMed] [Google Scholar]
  16. Scheen A., Luyckx A. S., De Graeve J. Cardiovascular effects of intravenous tolmesoxide in hypertensive patients. Arch Int Pharmacodyn Ther. 1981 Jun;251(2):322–334. [PubMed] [Google Scholar]
  17. Silas J. H., Phillips F. C., Freestone S., Tucker G. T., Ramsay L. E. A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. Eur J Clin Pharmacol. 1981 Jan;19(2):113–118. doi: 10.1007/BF00568397. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES